Predictive models for nanotoxicology: current challenges and future opportunities. by Clark Katherine, A. et al.
 1 
Clark, K.A.; White, R.H..; Silbergeld, R.K. Predictive models for 
nanotoxicology: current challenges and future opportunities. 
Regulatory Toxicology and Pharmacology, 59(3):361-363, 2011. 
 
 
Postprint version 
 
Final draft post-refereeing 
Journal website 
 
http://www.sciencedirect.com/science/journal/02732300  
Pubmed link 
 
http://www.ncbi.nlm.nih.gov/pubmed/21310205   
 
DOI 
 
10.1016/j.yrtph.2011.02.002 
 
 
 
 
  
 2 
Title: Predictive models for nanotoxicology: current challenges and future opportunities  
 
Authors:  
Clark, Katherine A.
1*
; White, Ronald H.
2
; Silbergeld, Ellen K.
1
 
1 Johns Hopkins University, Bloomberg School of Public Health, Dept. of Environmental 
Health Sciences; 
2
 Johns Hopkins University, Bloomberg School of Public Health, Dept. 
of Health Policy and Management 
*corresponding author 
 
Contact information authors: 
Katherine A. Clark* 
Johns Hopkins University Bloomberg School of Public Health 
Institute for Work and Health, Universities of Lausanne and Geneva 
Rue de Bugnon 21 
1011 Lausanne 
Switzerland 
Ph :+41 (0) 79 629 47 28 
Fax :+41 (0) 21 314 74 30 
kclark@jhsph.edu 
Katherine.clark@hospvd.ch 
 
Ronald H. White 
Johns Hopkins University Bloomberg School of Public Health 
624 N. Broadway 
Baltimore, MD 21205 
rwhite@jhsph.edu 
 
Ellen K. Silbergeld 
Johns Hopkins University Bloomberg School of Public Health 
615 N. Wolfe St. 
Baltimore, MD 21205 
esilberg@jhsph.edu 
 
 
 
 3 
Abstract 
Characterizing the risks posed by nanomaterials is extraordinarily complex because these 
materials can have a wide range of sizes, shapes, chemical compositions and surface 
modifications, all of which may affect toxicity. There is an urgent need for a testing 
strategy that can rapidly and efficiently provide a screening approach for evaluating the 
potential hazard of nanomaterials and inform the prioritization of additional toxicological 
testing where necessary. Predictive toxicity models could form an integral component of 
such an approach by predicting which nanomaterials, as a result of their physico-
chemical characteristics, have potentially hazardous properties.  Strategies for directing 
research towards predictive models and the ancillary benefits of such research are 
presented here.  
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One of the greatest challenges for assessing the potential risks of manufactured 
nanomaterials (MNMs) is the lack of a rational evidence-based system for inferring the 
hazard of nanomaterials. This is particularly problematic in light of the increasing 
number of MNMs in commerce. The unique properties of MNMs, largely a function of 
their small size and associated high surface-area to volume ratio, can result in increased 
transport across membranes, binding to biological macromolecules, transport of 
molecules, biocidal properties, or may even result in biological properties that have not 
yet been predicted or recognized for nanomaterials. These properties, depending on the 
situation or purpose, may be beneficial, such as when optimized for drug delivery, but 
also may pose health and/or environmental risks as a result of unintentional exposures or 
environmental release.  
 
Within a single class of MNMs (e.g., carbon-based nanomaterials, metal oxide 
nanoparticles), there can be a wide range of sizes and shapes, with different chemical 
composition and surface modifications, all of which may affect behavior and toxicity. 
When considering the variety of nanomaterials that are currently or will in the future be 
produced and used, it is clearly infeasible to evaluate hazard by testing all of these 
MNMs on a case-by-case basis, particularly with mammalian tests. Yet, for lack of a 
system for evaluating MNM hazard, there is little opportunity to compare the results of 
different studies or isolate factors that may translate into increased hazard and risks. The 
difficulties in assessing the risks of MNMs are well-recognized. Several articles have 
been published in recent years that outline options and challenges for applying traditional 
and alternative risk assessment strategies to MNM, both in terms of human and 
environmental risk (Grieger et al., 2010; Johnston et al., 2010; Linkov et al., 2007; 
Linkov et al., 2009; Morgan, 2005; Shatkin et al., 2010; Tervonen et al., 2009). 
Prominent among the alternative methods are the use of multi-criteria decision analysis 
(MCDA) and expert elictation, which incorporate expert judgment to a greater extent 
than traditional risk assessment methods. The over-arching theme of all these articles is 
the need for more data to conduct risk assessments that inform risk-based decision-
making for nanomaterials. 
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A more intensive effort towards the development of predictive toxicity models is urgently 
needed. Predictive models have been used for decades to rapidly evaluate the potential 
hazard of chemicals for which there are inadequate or no data on potential hazard, as is 
the case for new chemicals evaluated under the US Toxic Substances Control Act. In 
addition, the use of these methods has been adopted under the High Production Volume 
Chemical Programs and the European REACH legislation (EPA, 1999; Hartung and 
Hoffmann, 2009; OECD, 2004). In parallel, the US EPA has recently released a report 
outlining the needs, in terms of environmental fate and transport of MNMs, for 
developing predictive models (Johnston et al., 2010). Efforts to address the human 
toxicity of nanomaterials should be directed towards developing models that predict 
associations between changes to MNM physico-chemical characteristics and hazardous 
properties. For example, small changes to size or surface functional groups may affect 
whether a MNM can cross physiological barriers, how it can interact with cellular 
structures, and ultimately, the types of responses it can initiate. If these relationships were 
understood, it would assist in developing safer MNMs, screening MNMs for regulatory 
purposes, and prioritizing MNMs for more comprehensive toxicological testing. 
 
Several approaches to building predictive models in toxicology exist, ranging from 
relatively simple read-across methods to more complex computational models (e.g., 
QSARs). Regardless of model type and associated terminology, predictive models are 
developed by categorizing toxicological data by a concept of relational characteristics, 
with representative substances in a category used to infer toxicological information about 
other substances that can be assigned to the same category (OECD, 2007). The 
development of predictive models, particularly computational models, requires large 
amounts of high quality data. Data that are not sufficiently informative in the 
development of predictive models include data that are collected using diverse methods, 
that do not include a detailed description of the tested materials, measure different 
endpoints (or use different methods for quantifying endpoints), or are focused on one or a 
few MNMs. Several factors can hinder the development and predictive ability of models, 
thus presenting significant challenges to the development of predictive models for all 
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endpoints or classes of materials. These factors include limitations in the availability of 
the data needed to build models, in the understanding mechanism of action, and in the 
definition of the chemical space for which the model can be used (Cronin et al., 2003; 
Hartung and Hoffmann, 2009; Zvinavashe et al., 2008).  However, the state-of-the-
science for modeling of chemical-biological interactions is advancing, in part due to the 
continued development of high throughput testing and associated data analysis as well as 
advances in the understanding of the biological basis (e.g., modes of action) for chemical-
induced health impacts (Rusyn and Daston, 2010). 
 
Due to the differences between MNMs and the substances that are more traditionally the 
subjects of predictive modeling (i.e., molecules), the descriptors for building models for 
MNMs will necessarily be different and pose a significant challenge for toxicology 
(SCENIHR 2007). Puzyn, et al. (2009) discuss in detail the potential and challenges for 
developing nano-QSARs and provide examples of some initial QSARs developed for 
MNMs. The authors are optimistic that this methodology can successfully be applied to 
MNMs. Fourches, et al. (2010) have successfully developed two QNARs (quantitative 
nanostructure-activity relationships) using two large datasets from in vitro assays. Both 
models were statistically validated and externally predictive.  
 
There are several aspects to a research strategy for developing predictive models for 
MNMs. First, there must be greater standardization at all stages of the toxicity studies, 
from starting materials to endpoint(s). Although standardization risks inhibiting 
flexibility and innovation in study design, for the purposes of developing models, data 
collected in the same manner are needed. Several organizations are currently evaluating 
testing protocols and developing guidelines and reference materials, including OECD, the 
International Organization for Standardization (ISO), and various other international 
projects. Material characterization continues to present a significant hurdle in terms of 
resources (e.g., costs and expertise) to many toxicologists: the continued development of 
well-characterized standardized reference materials for toxicity testing should assist in 
this area. Second, studies should be designed in ways that specifically and systematically 
evaluate the role of physico-chemical properties in MNM behavior. For example, a study 
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that tests the effect of a range of surface modifications on oxidative stress will be far 
more informative than one that measures oxidative stress following exposure to a single 
MNM. In general, systematic testing of variations on a MNM property (e.g., charge, size, 
surface properties, etc.) are needed to identify how physico-chemical properties influence 
biological activity. Finally, an open system for storing and sharing information is needed. 
Referring to the peer-reviewed literature for data is not useful because details are often 
missing, this system of sharing information is subject to publication bias (i.e., non-
publishing of negative results) and many industry studies are not published. Successful 
data sharing systems must function in a way that users can enter data for sharing and 
access other data, all while maintaining confidentially of sensitive information to 
encourage broader participation. The DEREK system for predicting toxicity and the 
National Cancer Institute’s caNanoLab provide examples of systems that could be 
adapted to a larger scale for sharing data (Gaheen et al., 2009; Marchant et al., 2008). 
 
There are also secondary benefits from investing in the effort needed to develop 
predictive models, independent of models themselves. As noted above, only limited data 
are currently available for conducting hazard evaluations, and there is little agreement on 
the base set of toxicity assays and associated information needed to inform hazard 
assessment. A commitment to develop predictive models for nanomaterials will focus 
needed attention on improved nano-specific assays and developing open, curated 
databases of such knowledge. Alternative approaches for prioritizing risks in data poor 
areas, such as MCDA and expert elicitation, could also benefit from (and inform) the 
development of such information (Linkov et al., 2009; Tervonen et al., 2009). 
Additionally, the development of predictive models requires information that is focused 
primarily on interactions at the molecular and cellular level. It is generally recognized 
that high throughput/in vitro testing methods are needed to characterize the hazards of the 
large number of MNMs in production and use (Hartung, 2010). Such a research goal is 
well-aligned with recent European Union regulations seeking to minimize research in 
animals and efforts in the United States to better develop in vitro and in silico toxicology 
(NRC, 2007; Schoeters, 2010). As part of this effort, it is also critical to develop a basis 
for inferring relationships between in vitro and in vivo data for predicting human health 
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hazards (Warheit, 2010). Finally, as the field of nanotoxicology is relatively young, it is 
an ideal time to implement new and innovative strategies for testing. The successes and 
failures of these efforts can be used to inform toxicity l testing and associated risk 
assessment and risk management policy for other chemical classes or novel  
technological areas that have not been the target of increased research interest or 
coincided with efforts towards more advanced or alternative toxicity testing methods 
(Hartung, 2010). 
 
The novel and advanced properties of MNMs calls for a novel and advanced approach to 
their testing. Several scientists have mentioned or urged the development of QSARs or 
other predictive models for MNMs (ICON, 2008; Meng et al., 2009). However, the 
concerted action to develop such an approach, both through funding mechanisms and the 
standardization of research methods (with predictive models in mind) is lacking. Now 
that there are initial efforts showing promise in the area of predictive models for MNMs, 
efforts must be made to increase the momentum in this area. As nanotechnology is 
redefining how we manufacture and use materials, it is only appropriate that health 
scientists meet this innovation with some innovation of their own.  
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